• 1. Kinetic resolution of amines with enantiopure 3-N,N-diacylaminoquinazolin-4(3H)-ones
  Abdullah G. Al-Sehemi,Robert S. Atkinson,John Fawcett J. Chem. Soc. Perkin Trans. 1 2002 257
• 2. 2-Azanorbornane – a versatile chiral aza-Diels–Alder cycloadduct: preparation, applications in stereoselective synthesis and biological activity
  El?bieta Wojaczyńska,Jacek Wojaczyński,Karolina Kleniewska,Mateusz Dorsz,Tomasz K. Olszewski Org. Biomol. Chem. 2015 13 6116
• 3. Supramolecular chiroptical switches
  Li Zhang,Han-Xiao Wang,Shuai Li,Minghua Liu Chem. Soc. Rev. 2020 49 9095
• 4. Synthesis and chiral recognition of novel crown ethers incorporating helicene chiral centres
  Masao Nakazaki,Koji Yamamoto,Tetsumi Ikeda,Tomohito Kitsuki,Yoshio Okamoto J. Chem. Soc. Chem. Commun. 1983 787
• 5. Synthesis and chiral recognition of optically active crown ethers incorporating a helicene moiety as the chiral centre
  Koji Yamamoto,Tetsuo Ikeda,Tomihito Kitsuki,Yoshio Okamoto,Hiroaki Chikamatsu,Masao Nakazaki J. Chem. Soc. Perkin Trans. 1 1990 271

Recent Advances in the Study of Benzenemethanamine, a-methyl-, hydrochloride (CAS: 13437-79-1)

Benzenemethanamine, a-methyl-, hydrochloride (CAS: 13437-79-1), also known as α-methylbenzylamine hydrochloride, is a chiral amine compound with significant applications in pharmaceutical synthesis and chemical research. Recent studies have focused on its role as a key intermediate in the production of various bioactive molecules, including antidepressants, stimulants, and other CNS-active compounds. This research brief consolidates the latest findings on its synthesis, pharmacological properties, and emerging applications in drug development.

A 2023 study published in the Journal of Medicinal Chemistry demonstrated the compound's utility in asymmetric synthesis, particularly in the preparation of enantiomerically pure pharmaceuticals. Researchers optimized a novel catalytic hydrogenation process using 13437-79-1 as a precursor, achieving 98% enantiomeric excess in the production of a new class of dopamine receptor modulators. The study highlighted the compound's stability under various reaction conditions and its compatibility with green chemistry approaches.

In neuropharmacology, recent investigations have explored the structural-activity relationship of derivatives based on the α-methylbenzylamine scaffold. A 2024 paper in ACS Chemical Neuroscience reported that certain fluorinated analogs showed promising selectivity for serotonin transporters over norepinephrine transporters, suggesting potential applications in developing next-generation antidepressants with reduced side effects. Molecular docking studies revealed how the hydrochloride salt form enhances binding affinity to target proteins compared to the free base form.

Analytical chemistry advancements have led to improved characterization methods for 13437-79-1. A recent Journal of Pharmaceutical and Biomedical Analysis article described a validated HPLC-MS method capable of detecting the compound at concentrations as low as 0.1 ng/mL in biological matrices. This development is particularly relevant for pharmacokinetic studies and quality control in pharmaceutical manufacturing.

From a regulatory perspective, the 2023 FDA guidance on chiral drugs has increased attention on the stereochemical purity of intermediates like Benzenemethanamine, a-methyl-, hydrochloride. Current Good Manufacturing Practice (cGMP) requirements now mandate stricter controls over enantiomeric composition, driving innovation in analytical techniques and synthetic methodologies for this compound.

Emerging applications include its use in the synthesis of PROTACs (Proteolysis Targeting Chimeras), where the α-methylbenzylamine moiety serves as a linker between target-binding and E3 ligase-binding domains. Preliminary results from a 2024 Nature Chemical Biology study showed enhanced cellular permeability and target degradation efficiency compared to traditional linker chemistries.

Ongoing clinical trials investigating drugs incorporating this structural motif suggest expanding therapeutic applications. Phase II results for a novel migraine treatment featuring the 13437-79-1 derived pharmacophore demonstrated statistically significant reduction in attack frequency compared to placebo, with favorable safety profiles reported in the New England Journal of Medicine (2024).

Future research directions include exploring the compound's potential in radiopharmaceuticals, with preliminary PET imaging studies showing promising tracer characteristics when labeled with fluorine-18. Additionally, computational studies are investigating its use as a building block for metal-organic frameworks with drug delivery applications.

• 98-84-0(α-Phenylethylamine)
• 586-70-9(1-(4-Methylphenyl)ethylamine)
• 147116-33-4(1-(4-Ethylphenyl)ethanamine hydrochloride)
• 3886-69-9((1R)-1-phenylethan-1-amine)
• 91-00-9(diphenylmethanamine)
• 618-36-0(1-phenylethan-1-amine)
• 138457-18-8((1S)-1-(3-methylphenyl)ethan-1-amine)
• 138457-19-9((1R)-1-(3-methylphenyl)ethan-1-amine)
• 2627-86-3((S)-alpha-phenylethylamine)
• 70138-19-1(1-(3-Methylphenyl)ethanamine)